Genmab A/S

Equities

GMAB

DK0010272202

Market Closed - Nasdaq Copenhagen Other stock markets 08:50:00 20/09/2024 pm IST			5-day change	1st Jan Change
1,715.00 ^DKK	-2.83%		-4.72%	-20.42%

16/09	Genmab Reports 'Encouraging' Data From Phase 1/2 Study of Investigational Ovarian Cancer Drug	MT
16/09	Genmab Reports 'Encouraging Response Rate' from Investigational Ovarian Cancer Treatment Trial	MT

Presentation Operator MessageOperator (Operator)Hello, and welcome to the Genmab First Half 20...

This article is reserved for subscribers

To unlock the article, SUBSCRIBE!

Vous êtes déja client ? Log In

Latest news about Genmab A/S

Genmab Reports 'Encouraging' Data From Phase 1/2 Study of Investigational Ovarian Cancer Drug	16/09	MT
Genmab Reports 'Encouraging Response Rate' from Investigational Ovarian Cancer Treatment Trial	16/09	MT
Genmab Announces New Data from the Phase 1/2 Study Of Rinatabart Sesutecan (Rina-S), an Investigational Folate Receptor-Alpha-Targeted, Topo1 Antibody-Drug Conjugate	15/09	CI
Truist Lowers Price Target on Genmab to $50 From $53, Maintains Buy Rating	09/09	MT
Genmab A/S Presents at Morgan Stanley 22nd Annual Global Healthcare Conference, Sep-04-2024 01:05 PM	04/09
Morgan Stanley Upgrades Genmab to Equalweight, Price Target is $31	04/09	MT
HOOKIPA Pharma Names Julie O'Neill Nonexecutive Chair	30/08	MT
European Equities Close Lower in Tuesday Trading; Euro Area, EU Inflation Rises Slightly	20/08	MT
Global markets live: Rio Tinto, GSK, Palo Alto, GM, Lowe's...	20/08
Genmab Wins Conditional EU Approval for Follicular Lymphoma Antibody	20/08	MT
AbbVie, Genmab Lymphoma Treatment Gets European Commission Marketing Authorization	20/08	DJ
Genmab, AbbVie Get Conditional European Commission Approval for Lymphoma Treatment	20/08	MT
Genmab A/S Receives Second European Commission Approval for the Treatment of Adults with Relapsed/Refractory Follicular Lymphoma	19/08	CI
Genmab Names First Chief Technology, Chief Commercial Officers; COO to Exit	16/08	MT
Genmab COO Anthony Mancini Departs; Firm Names New CTO, CCO	16/08	MT
Genmab Operations Chief Anthony Mancini Departing	16/08	MT
Genmab A/S Announces Executive Changes	16/08	CI
AbbVie Inc. Announces Ontario and Quebec Are First Provinces to Reimburse Subcutaneous Epkinly? (Epcoritamab) for the Treatment of Diffuse Large B-Cell Lymphoma Under New Early Access Process	15/08	CI
GENMAB : Better-than-expected Q2 + guidance upgrade	09/08
Genmab: updates 2024 financial forecasts	09/08	CF
Genmab's Interim Q2 Earnings, Revenue Climb; Increases 2024 Revenue Guidance	09/08	MT
Genmab Posts Higher H1 Profit; Revenue Advances	09/08	MT
Genmab A/S, H1 2024 Earnings Call, Aug 08, 2024	08/08
Genmab A/S Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2024	08/08	CI
Global markets live: Amazon, Intel, Boeing, Robinhood, KKR, Zillow...	08/08